Comparative Pharmacology
Head-to-head clinical analysis: AQVESME versus LACRISERT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AQVESME versus LACRISERT.
AQVESME vs LACRISERT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AQVESME is a phospholipase A2 inhibitor that reduces the hydrolysis of phospholipids into lysophospholipids and free fatty acids, thereby attenuating the release of inflammatory mediators and decreasing blood-brain barrier permeability. It also exhibits antioxidant and anti-apoptotic properties.
LACRISERT (hydroxypropyl cellulose ophthalmic insert) acts as a lubricant to stabilize and thicken the precorneal tear film, prolonging tear film breakup time and protecting the ocular surface. It does not have pharmacological activity.
5 mg/kg via IV infusion over 1 hour every 2 weeks
One 5 mg ophthalmic insert placed into the inferior cul-de-sac of the eye once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; extended to 24-36 hours in moderate renal impairment (CrCl 30-50 mL/min).
Not applicable; local ocular insert, no systemic half-life.
Primarily renal (70-80% as unchanged drug), with 20-30% biliary/fecal elimination.
Not systemically absorbed; no renal or biliary elimination.
Category C
Category C
Ophthalmic Lubricant
Ophthalmic Lubricant